Proven
neurotechnology
built for the
real world
Control Bionics delivers objective, non-invasive neural-signal technology, proven in clinical environments, and built to scale across performance, rehabilitation, medical, research, and assistive communication.
Proven
neurotechnology
built for the
real world
Control Bionics delivers objective, non-invasive neural-signal technology, proven in clinical environments, and built to scale across performance, rehabilitation, medical, research, and assistive communication.
Capability
From signal to actionable insight
The Control Bionics neural-signal platform captures physiological data with medical-grade precision and converts it into measurable, decision-ready outcomes. Built for deployment across clinical, research, and performance environments — and validated where it counts.
Signal acquisition and processing
Real-time analysis and validation
Clinical integration and reporting
Technology
The platform serves distinct markets with precision and measurable outcomes. One underlying technology - four applications.
A platform built for clinical deployment
Medical-grade signal processing meets real-world clinical environments. Designed for integration, validation, and measurable outcomes.
Non-invasive neural signal capture
Physiological data without surgical intervention or implantation. Validated for use in complex clinical environments.
Regulatory pathway established
Cleared for clinical use with ongoing validation across multiple applications — FDA, TGA, and CE registered.
Outcome-focused architecture
Platform designed to deliver decision-ready insights, not only raw data. Built to integrate into clinical and research workflows.
Evidence from clinical and research deployment
Control Bionics technology is validated through research, clinical trials, and real-world deployment across rehabilitation, performance, and research settings.
1,000s of users
Trusted by individuals, clinicians, and organisations across four markets
Government and privately funded
Approved for funding through Medicare, Medicaid, NDIS, and private insurance pathways.
100%
Non-invasive signal acquisition
3 Regulatory clearances
(FDA, TGA, CE)
Latest from our platform
Research, clinical validation and platform developments.
Control Bionics (ASX:CBL) Partners with Numotion as Northeastern US Reseller of Assistive Technology Solutions
Control Bionics, a global assistive technology company specializing in speech generating devices, announced it is partnering with Numotion, a leading provider of Complex Rehab Technology (CRT) to offer the Control Bionics’ Trilogy product line.
Control Bionics set to enter the ASX bourse next week; inspired by Stephen Hawking and already FDA approved
Medtech company Control Bionics (ASX:CBL) will list on the ASX next week. The company’s EMG (electromyography)-based technology helps people with disabilities inhibiting communications to do so through electronic devices that pick up their neuroelectric...
Control Bionics Launches Latest Product Extension
Control Bionics announces the newest addition to its Augmentative and Alternative Communication (AAC) device line, the GridPad Trilogy™ communication solution. The new neuro-based voice output communication aid is intended to help people living with paralysis and loss of speech find their voice.
Opening Back Up In-Person Assessments
As we’ve globally transitioned into telepresence communication, we will still be offering our remote assessments alongside our industry-leading customer support. We understand that some communication needs, and assessments, may be challenging to support remotely and we are pleased to be opening back up in-person meetings and assessments.
Select your path to neural-signal insights and outcomes
Explore how the platform integrates into clinical workflows and delivers decision-ready outcomes.
Learn more
Discover how researchers are using real-time neural data to power breakthrough studies.
LearnNDIS-registered provider
Control Bionics is a registered NDIS provider. Eligible participants can access our assistive communication devices and neurotechnology solutions through their NDIS plan.